Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolebrutinib in generalized Myasthenia Gravis
NCT05132569Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Dec 2021
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of tolebrutinib in myasthenia gravis (MG), sponsored by Sanofi. Started Dec 2021; status: terminated.
02
Drugs
tolebrutinib
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT05132569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05132569.